EDAP - エダップテクノメド (EDAP TMS S.A.) エダップテクノメド

 EDAPのチャート


 EDAPの企業情報

symbol EDAP
会社名 EDAP TMS S.A. (エダップテクノメド)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 イーディーエーピー・ティーエムエス(EDAP TMS S.A.)は限局性前立腺癌を治療するための高密度焦点式超音波(HIFU)療法用の機器である「Ablatherm」装置を開発・販売する会社。同社はHIFU事業と泌尿器科機器・サービス(UDS)事業(砕石術活動を含む)の2つ事業区分により構成される。この2部門を通して、同社は泌尿器疾患を対象とする低侵襲医療機器の開発・製造・販売を行う。HIFU療法は、副作用の発生率が低い局限性前立腺癌治療用の低侵襲治療法の選択であると見られている。Ablatherm-HIFU療法は通常で局限性前立腺癌(ステージT1及びT2)手術を受けない、または別のオプションを好む患者を治療対象にしている。この療法は放射線治療に失敗した患者にも応用される。また、同社はその他特定の腫瘍を治療するためのHIFU技術を開発している。   エダップテクノメドは、フランスの持株会社。子会社を通じ、主に泌尿器疾患向けの医療機器を開発、製造、販売する。事業は、HIFU(高密度終点式超音波治療法)とUDS(泌尿器科装置)の2部門で構成。米国における登録商標は、「エダップ」、「テクノメド」、HIFU「Ablatherm」、結石破砕装置「ソノリス」や「ソノリスアイシス」などがある。  EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
本社所在地 Parc d'Activites La Poudrette-Lamartine 4/6 rue du Dauphine Vaulx-en-Velin 69120 FRA
代表者氏名 Philippe Chauveau フィリップ・ショーボウ
代表者役職名 Independent Chairman of the Board
電話番号 +33 4-7215-3150
設立年月日 29190
市場名 NASDAQ National Market System
ipoyear 1997年
従業員数 200人
url www.edap-tms.com
nasdaq_url https://www.nasdaq.com/symbol/edap
adr_tso 29342294
EBITDA EBITDA(百万ドル) -3.05722
終値(lastsale) 2.99
時価総額(marketcap) 87733459.06
時価総額 時価総額(百万ドル) 81.18656
売上高 売上高(百万ドル) 40.80078
企業価値(EV) 企業価値(EV)(百万ドル) ー
当期純利益 当期純利益(百万ドル) -1.48667
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Edap Tms SA (ADR) revenues decreased 1% to EUR17.8M. Net loss increased from EUR66K to EUR678K. Revenues reflect Sales of goods decrease of 5% to EUR10.9M Net Sales of RPP and Leases decrease of 5% to EUR2.5M Other revenues decrease of 64% to EUR14K. Higher net loss reflects Interest (expense) income net decrease of 63% to EUR528K (income).

 EDAPのテクニカル分析


 EDAPのニュース

   EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020  2020/05/06 12:30:00 GlobeNewswire
Company to host conference call and webcast on Thursday, May 14 at 8:30 am EDT LYON, France, May 6, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global…
   Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson  2020/03/24 11:01:00 Benzinga Feeds
DUBLIN , March 24, 2020 /PRNewswire/ -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering. The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic. As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   EDAP TMS S.A. (EDAP) Shares March Higher, Can It Continue?  2019/09/06 14:07:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).
   EDAP TMS S.A. (EDAP) Upgraded to Strong Buy: Here's Why  2019/09/06 13:00:07 Zacks Investment Research
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020  2020/05/06 12:30:00 GlobeNewswire
Company to host conference call and webcast on Thursday, May 14 at 8:30 am EDT LYON, France, May 6, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global…
   Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson  2020/03/24 11:01:00 Benzinga Feeds
DUBLIN , March 24, 2020 /PRNewswire/ -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering. The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic. As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   EDAP TMS S.A. (EDAP) Shares March Higher, Can It Continue?  2019/09/06 14:07:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).
   EDAP TMS S.A. (EDAP) Upgraded to Strong Buy: Here's Why  2019/09/06 13:00:07 Zacks Investment Research
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020  2020/05/06 12:30:00 GlobeNewswire
Company to host conference call and webcast on Thursday, May 14 at 8:30 am EDT LYON, France, May 6, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global…
   Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson  2020/03/24 11:01:00 Benzinga Feeds
DUBLIN , March 24, 2020 /PRNewswire/ -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering. The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic. As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   EDAP TMS S.A. (EDAP) Shares March Higher, Can It Continue?  2019/09/06 14:07:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).
   EDAP TMS S.A. (EDAP) Upgraded to Strong Buy: Here's Why  2019/09/06 13:00:07 Zacks Investment Research
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

 関連キーワード  (先端医療機器_テクノロジ― 米国株 エダップテクノメド EDAP EDAP TMS S.A.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)